AR009135A1 - Composiciones farmaceuticas, proceso para su preparacion y articulo de manufactura que comprenden dicha composicion. - Google Patents

Composiciones farmaceuticas, proceso para su preparacion y articulo de manufactura que comprenden dicha composicion.

Info

Publication number
AR009135A1
AR009135A1 ARP970105027A ARP970105027A AR009135A1 AR 009135 A1 AR009135 A1 AR 009135A1 AR P970105027 A ARP970105027 A AR P970105027A AR P970105027 A ARP970105027 A AR P970105027A AR 009135 A1 AR009135 A1 AR 009135A1
Authority
AR
Argentina
Prior art keywords
starch
composition
manufacture
magnesium
stearate
Prior art date
Application number
ARP970105027A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR009135A1 publication Critical patent/AR009135A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Una composicion farmacéutica y un método para inhibir de inmunodeficiencia humana (VIH) el cual comprende administrar a un paciente infectado por VIH unacombinacion homogénea de lamivudina (2R, cis)-4 amino-1-(2-hidroximetil-1,3- oxatiolan-5-5l)-(1H)-pirimidin-2-ona, zidovudina (3-ácido-3-desoxitimidina) yun lubricante farmacéutico que se selecciona del grupo que consiste de dioxido de silicio fumante, aluminosilicato de sodio, silicato de calcio, celulosapulverizada, celulosa microcristalina, almidon de maiz, benzoatos de sodio, carbonato de calcio, carbonato de magnesio, talco libre de asbestos, esteratosmetálicos, estearato de calcio, estearato de magnesio, estearato de zinc, estearowet C(R), almidon, almidon 1500, laurilsulfato de magnesio, u oxido demagnesio en una cantidad que logra eficacia antiviral. El artículo comprende un material de empaque y dicha composicion. El uso de la lamivudina o un derivadofarmaceuticamente aceptable de la misma, zidovudina o un derivado farmaceuticamente aceptable en la manufactura de un medicamento.
ARP970105027A 1996-10-31 1997-10-29 Composiciones farmaceuticas, proceso para su preparacion y articulo de manufactura que comprenden dicha composicion. AR009135A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9622681.6A GB9622681D0 (en) 1996-10-31 1996-10-31 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
AR009135A1 true AR009135A1 (es) 2000-03-08

Family

ID=10802224

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105027A AR009135A1 (es) 1996-10-31 1997-10-29 Composiciones farmaceuticas, proceso para su preparacion y articulo de manufactura que comprenden dicha composicion.

Country Status (44)

Country Link
EP (1) EP0941100B1 (es)
JP (1) JP2001502718A (es)
KR (1) KR100551652B1 (es)
AP (1) AP1067A (es)
AR (1) AR009135A1 (es)
AT (1) ATE241364T1 (es)
AU (1) AU736607B2 (es)
BG (1) BG64541B1 (es)
BR (1) BR9712614A (es)
CA (1) CA2270174A1 (es)
CO (1) CO4930269A1 (es)
CY (1) CY2485B1 (es)
CZ (1) CZ296080B6 (es)
DE (1) DE69722433T2 (es)
DK (1) DK0941100T3 (es)
EA (1) EA002437B1 (es)
EE (1) EE03806B1 (es)
ES (1) ES2200204T3 (es)
GB (1) GB9622681D0 (es)
GE (1) GEP20022735B (es)
GT (1) GT199700116A (es)
HK (1) HK1020880A1 (es)
HR (1) HRP970569B1 (es)
HU (1) HU224969B1 (es)
ID (1) ID18698A (es)
IL (1) IL129422A0 (es)
IS (1) IS5024A (es)
MY (1) MY119513A (es)
NO (1) NO317163B1 (es)
NZ (1) NZ335153A (es)
OA (1) OA11038A (es)
PA (1) PA8441101A1 (es)
PE (1) PE10099A1 (es)
PL (1) PL190349B1 (es)
PT (1) PT941100E (es)
SI (1) SI0941100T1 (es)
SK (1) SK284286B6 (es)
SV (1) SV1997000090A (es)
TR (1) TR199900950T2 (es)
UA (1) UA64725C2 (es)
UY (1) UY24766A1 (es)
WO (1) WO1998018477A2 (es)
YU (1) YU19999A (es)
ZA (1) ZA979726B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
DE60219965T2 (de) * 2002-04-23 2008-01-17 Lupin Ltd., Mumbai Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine
DE60313657T2 (de) * 2002-11-08 2008-01-03 Smithkline Beecham Corp. Antivirale zusammensetzungen
AU2004206827A1 (en) 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
WO2011156594A2 (en) 2010-06-09 2011-12-15 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
CN104203244A (zh) 2012-03-05 2014-12-10 希普拉有限公司 包含拉米夫定、festinnvir和奈韦拉平的抗反转录病毒药物组合物
WO2014130553A2 (en) * 2013-02-20 2014-08-28 Abbvie Inc. Tablet dosage forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
WO1992020344A1 (en) * 1991-05-16 1992-11-26 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
GB9110624D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Combinations
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
CO4930269A1 (es) 2000-06-27
SV1997000090A (es) 1998-10-07
IS5024A (is) 1999-04-09
NO992091D0 (no) 1999-04-29
EE03806B1 (et) 2002-08-15
BR9712614A (pt) 1999-10-26
AU5314298A (en) 1998-05-22
EP0941100B1 (en) 2003-05-28
TR199900950T2 (xx) 1999-07-21
BG64541B1 (bg) 2005-07-29
ZA979726B (en) 1999-04-29
EP0941100A2 (en) 1999-09-15
WO1998018477A2 (en) 1998-05-07
PL190349B1 (pl) 2005-11-30
PE10099A1 (es) 1999-03-02
NO992091L (no) 1999-06-29
EA199900345A1 (ru) 2000-02-28
AP1067A (en) 2002-05-01
CZ155799A3 (cs) 1999-10-13
CA2270174A1 (en) 1998-05-07
AP9901519A0 (en) 1999-06-30
UY24766A1 (es) 2000-12-29
ES2200204T3 (es) 2004-03-01
BG103435A (en) 2000-04-28
CY2485B1 (en) 2005-06-03
JP2001502718A (ja) 2001-02-27
IL129422A0 (en) 2000-02-17
PL333143A1 (en) 1999-11-22
CZ296080B6 (cs) 2006-01-11
UA64725C2 (uk) 2004-03-15
ID18698A (id) 1998-04-30
OA11038A (en) 2002-02-06
AU736607B2 (en) 2001-08-02
GB9622681D0 (en) 1997-01-08
HRP970569B1 (en) 2004-10-31
KR20000052893A (ko) 2000-08-25
KR100551652B1 (ko) 2006-02-13
MY119513A (en) 2005-06-30
SK57599A3 (en) 2000-06-12
DE69722433D1 (de) 2003-07-03
ATE241364T1 (de) 2003-06-15
WO1998018477A3 (en) 1998-06-18
NZ335153A (en) 2001-04-27
DE69722433T2 (de) 2004-04-08
NO317163B1 (no) 2004-08-30
GEP20022735B (en) 2002-07-25
SI0941100T1 (en) 2003-12-31
EA002437B1 (ru) 2002-04-25
DK0941100T3 (da) 2003-09-01
HUP0000344A3 (en) 2002-04-29
SK284286B6 (sk) 2005-01-03
EE9900175A (et) 1999-12-15
GT199700116A (es) 1999-04-22
HU224969B1 (en) 2006-04-28
HUP0000344A2 (hu) 2001-05-28
HRP970569A2 (en) 1998-08-31
HK1020880A1 (en) 2000-05-26
PA8441101A1 (es) 2000-05-24
PT941100E (pt) 2003-10-31
YU19999A (sh) 2000-10-30

Similar Documents

Publication Publication Date Title
CO4960646A1 (es) Tabletas de metilcelulosa rapidamente desintegrables
TR199800894T2 (xx) Biyo-yap��kan kat� dozaj formlar�.
AR009135A1 (es) Composiciones farmaceuticas, proceso para su preparacion y articulo de manufactura que comprenden dicha composicion.
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
MX9801305A (es) Composicion de disolucion rapida oral para agonistas de dopamina.
ES2159591T3 (es) Composicion de liberacion controlada.
BR0213288A (pt) Etilcelulose altamente compressìvel para formação de comprimidos
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
AR041089A1 (es) Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
ES2103587T3 (es) Composiciones terapeuticas ingeribles, estables y absorbibles de nadh y de nadph.
BR0111868A (pt) Composições farmacêuticas
BR0311327A (pt) Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo
BR0117147A (pt) preparado de dosagem oral de desintegração instantánea
ES2264912T1 (es) Formulacion solida estable de sal de enalapril y procedimiento de preparacion de la misma.
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
BR0013106A (pt) Composição farmacêutica flutuante, comprimido, e processo de prepapação de um comprimido.
KR970706802A (ko) 저압-타정된 발포 제제(low-pressure tableted effervescent preparation)
AR011697A1 (es) Composiciones farmaceuticas, uso de lamivudina en la manufactura de tales composiciones farmaceuticas.
KR890006235A (ko) 피페리디노알칸올용 제약 조성물
AR002972A1 (es) Pildoras que tienen una matriz farmaceutica que proporcionan un perfil apropiado de liberacion de la droga, composicion para la preparacion de dichamatriz, proceso para preparar dichas pildoras y formas de dosificacion de dicha composicion.
MX2024006239A (es) Composicion farmaceutica solida que contiene el compuesto indocianina.
ES2113136T3 (es) Composiciones farmaceuticas de gemfibrozil y procedimiento para su preparacion.
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.
BR0210063A (pt) Composição estável e uso da mesma
PT1411956E (pt) Utilizacao de polissacaridos sobre-sulfatados como inibidores de vih

Legal Events

Date Code Title Description
FB Suspension of granting procedure